<DOC>
	<DOCNO>NCT00718471</DOCNO>
	<brief_summary>Randomized evaluation enoxaparin ( 0.5mg/kg IV ) versus UFH ( 50-70IU/kg GPIIb/IIIa inhibitor ; 70-100IU without GPIIb/IIIa inhibitor ) . Anticoagulation continue procedure use agent allocate per randomization ( enoxaparin SC , UHF IV SC )</brief_summary>
	<brief_title>STEMI Treated With Primary Angioplasty Intravenous Lovenox Unfractionated Heparin ( UFH )</brief_title>
	<detailed_description>This study prospective , multicenter , multinational , randomize , active-control arm trial . The study population consist subject ST-segment elevation MI randomize within 24 hour symptom onset . Subjects present 12 24 hour symptom onset present recurrent persist chest pain and/or recurrent persist ST elevation suggest ongoing ischemia , indication primary PCI . Approximately 850 subject enrol approximately 50 site several country include Austria , France , Germany United States . Informed consent obtain subject meet inclusion exclusion criterion prior study related procedure . Subjects randomize begin treatment Emergency Department ambulance hospital room in-patient . Eligible subject randomize ( 1:1 ) receive either UFH IV bolus ( ACT-adjusted ) enoxaparin 0.50 mg/kg IV bolus without monitoring . Randomization treatment group perform use interactive voice response system ( IVRS ) . All treatment group give aspirin ( 160 500 mg/day accord local practice ) clopidogrel ( 300 900mg loading dose accord local practice ) . All concomitant medication consistent local standard care .</detailed_description>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>1 . Be least 18 year age . 2 . Has experience continuous ischemic ( cardiac ) symptom least 20 minute . 3 . Has onset symptom qualify acute MI within past 24 hour , plan primary PCI . Patients present 12 24 hour symptom onset still indication primary PCI , i.e . persistent ischemic symptom and/or persistent recurrent ST elevation 4 . Has ECG indicative acute STEMI showing : ≥ 2 mm ST elevation 2 contiguous precordial ECG lead ( anterior infarction ) ; ≥ 1 mm ST elevation 2 contiguous limb ECG lead ( infarction ) ; New presumably new leave bundle branch block ( LBBB ) 5 . Shock patient eligible ( patient prolong cardiac arrest ) 6 . Be willing provide inform consent ( informed consent may provide legally authorize representative patient able provide ) . 7 . Agree comply protocolspecified procedure , include protocolmandated followup 1 . Use UFH LMWH anticoagulant agent ( Vit K antagonist , fondaparinux , bivalirudin ) within 48 hour prior randomization 2 . Thrombolytic therapy within previous 48 hour 3 . Known suspected pregnancy woman childbearing potential 4 . History hypersensitivity contraindication heparin LMWH 5 . Contraindication primary PCI excessive bleeding risk ( e.g . recent surgery ) suspect active internal bleeding 6 . Coexistent condition associate limited life expectancy short term ( e.g . advanced cancer ) 7 . Prolonged ( &gt; 10 minute ) cardiopulmonary resuscitation ( CPR ) 8 . Treatment investigational agent device within previous 30 day , plan use investigational drug device , previous enrolment trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>STEMI</keyword>
	<keyword>Primary PCI</keyword>
	<keyword>Anticoagulation</keyword>
</DOC>